SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

GLPG2938

Item No. 34318

CAS Registry No.:	2130996-00-6
Formal Name:	N-[2-ethoxy-6-(trifluoromethyl)-4-pyridinyl]-N′-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]-3-pyridazinyl]methyl]-urea
MF:	$C_{20}H_{19}F_6N_7O_2$
FW:	503.4
Purity:	≥98%
UV/Vis.:	λ_{max}: 217 nm
Supplied as:	A solid
Storage:	-20°C
Stability:	≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

GLPG2938 is supplied as a solid. A stock solution may be made by dissolving the GLPG2938 in the solvent of choice, which should be purged with an inert gas. GLPG2938 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of GLPG2938 in these solvents is approximately 1, 3, and 10 mg/ml, respectively.

Description

GLPG2938 is sphingosine-1-phosphate receptor 2 ($S1P_2$) antagonist.[1] It inhibits S1P-induced calcium flux in CHO cells overexpressing human $S1P_2$ (IC_{50} = 8.8 nM). GLPG2938 inhibits S1P-induced IL-8 release in HFL1 cells (IC_{50} = 0.6 nM) and S1P-induced contraction of human lung fibroblasts. *In vivo*, GLPG2938 (3, 10, and 30 mg/kg) prevents epithelial damage and pulmonary fibrosis, structural distortion, and inflammation in a mouse model of bleomycin-induced pulmonary fibrosis.

Reference

1. Mammoliti, O., Palisse, A., Joannesse, C., *et al.* Discovery of the S1P2 antagonist GLPG2938 (1-[2-ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a preclinical candidate for the treatment of idiopathic pulmonary fibrosis. *J. Med. Chem.* **64(9)**, 6037-6058 (2021).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM